stoxline Quote Chart Rank Option Currency Glossary
Akebia Therapeutics, Inc. (AKBA)
1.36  -0.03 (-2.16%)    04-19 16:00
Open: 1.35
High: 1.38
Volume: 2,856,005
Pre. Close: 1.39
Low: 1.31
Market Cap: 285(M)
Technical analysis
2024-04-19 5:07:38 PM
Short term     
Mid term     
Targets 6-month :  2.37 1-year :  2.89
Resists First :  2.03 Second :  2.48
Pivot price 1.48
Supports First :  1.3 Second :  1.08
MAs MA(5) :  1.38 MA(20) :  1.63
MA(100) :  1.46 MA(250) :  1.26
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  6.7 D(3) :  5.7
RSI RSI(14): 38.2
52-week High :  2.48 Low :  0.64
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AKBA ] has closed above bottom band by 11.0%. Bollinger Bands are 36.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.38 - 1.39 1.39 - 1.4
Low: 1.29 - 1.3 1.3 - 1.31
Close: 1.35 - 1.36 1.36 - 1.37
Company Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 17 Apr 2024
Akebia Therapeutics (AKBA) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Movies UK

Thu, 28 Mar 2024
U.S. FDA approves Akebia's anemia drug - Reuters

Wed, 27 Mar 2024
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney ... - PR Newswire

Tue, 19 Mar 2024
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise - Simply Wall St

Sun, 17 Mar 2024
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To ... - Yahoo Finance

Thu, 14 Mar 2024
Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 209 (M)
Shares Float 188 (M)
Held by Insiders 2.4 (%)
Held by Institutions 26.2 (%)
Shares Short 13,400 (K)
Shares Short P.Month 8,110 (K)
Stock Financials
EPS -0.29
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.16
Profit Margin -26.7 %
Operating Margin 5.2 %
Return on Assets (ttm) -9.4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0.6 %
Gross Profit (p.s.) 0
Sales Per Share 0.92
EBITDA (p.s.) -0.04
Qtrly Earnings Growth 0 %
Operating Cash Flow -23 (M)
Levered Free Cash Flow 22 (M)
Stock Valuations
PE Ratio -4.86
PEG Ratio 0
Price to Book value -8.5
Price to Sales 1.46
Price to Cash Flow -12.18
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android